NASDAQ
04.09.26 | 21:59
90,84 US-Dollar
+0,07 % +0,06
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | 177 | GlobeNewswire (Europe) | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.08. | Tarsus acquisition of Alkeus granted FTC early termination | 1 | Seeking Alpha | ||
| 07.08. | Tarsus joins Stargardt race to market with $800m Alkeus takeover | 2 | Pharmaceutical Technology | ||
| 06.08. | Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M | 1 | BioPharma Dive | ||
| 06.08. | Tarsus projects $685M-$705M in 2026 XDEMVY net product sales while advancing Alkeus acquisition | 1 | Seeking Alpha | ||
| 06.08. | Tarsus places $800m wager on Alkeus' Stargardt therapy | 3 | pharmaphorum | ||
| 06.08. | Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug | 1 | FierceBiotech | ||
| 06.08. | Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals | 2 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.43, revenue of $173.9M | 2 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 06.08. | Tarsus übernimmt Alkeus für 450 Mio. USD plus Meilensteinzahlungen | 8 | Investing.com Deutsch | ||
| 06.08. | Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million | 3 | Investing.com | ||
| 06.08. | Tarsus to acquire Alkeus for $450M upfront plus milestones | 2 | Investing.com | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | 451 | GlobeNewswire (Europe) | Generated second quarter 2026 XDEMVY- net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | 590 | GlobeNewswire (Europe) | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing | 314 | GlobeNewswire (Europe) | IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) ("Tarsus") today announced that it has entered into a securities purchase agreement with certain qualified... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.07. | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | 1 | Investing.com | ||
| 13.07. | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | 473 | GlobeNewswire (Europe) | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,214 | -1,89 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| MODERNA | 123,16 | -1,69 % | Moderna-Aktie: Kursschwäche bietet Einstiegschancen | Nach der spektakulären Kursexplosion der vergangenen Tage sucht die Moderna-Aktie weiter nach einem neuen Gleichgewicht. Der Erfolg des gemeinsam mit Merck entwickelten mRNA-Krebsimpfstoffs hat die... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,100 | +0,17 % | 3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| KUROS BIOSCIENCES | 19,500 | +4,39 % | Kuros Biosciences im Sinkflug: 37% Verlust seit Jahresbeginn alarmiert Anleger | ||
| ABIVAX | 97,55 | -0,61 % | Abivax has appointed James Berger as Global Head of Marketing | ||
| MINDMAZE THERAPEUTICS | 0,170 | -1,16 % | MindMaze Therapeutics Holding SA: MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences | MindMaze Therapeutics Holding SA
/ Key word(s): Conference
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences
01.09.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,520 | -0,66 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,280 | +0,50 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,234 | +1,09 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,220 | -3,59 % | NSE - ROCKET PHARMACEUTICALS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SYNDAX PHARMACEUTICALS | 17,635 | -0,45 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ASCENDIS PHARMA | 236,00 | +0,85 % | Ascendis Pharma: Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) | COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with... ► Artikel lesen | |
| JASPER THERAPEUTICS | 0,710 | +0,20 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,740 | +1,11 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion... ► Artikel lesen |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 90,84 Euro und damit +0,07 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.